** Brokerage Leerink Partners downgrades drug developer Compass Therapeutics CMPX.O to "market perform" from "outperform," cuts PT to $4 from $5
** Cites "uncertainties" in CMPX's experimental drug, CTX-009, developed for colorectal cancer that affects the large intestine
** Brokerage says it is disappointed by the drug's 5% response rate in Western patients, compared with 33% in South Korean ones; response rate refers to the proportion of patients whose tumors shrank or disappeared
** Leerink says the drug also needs to show a benefit for patient survival, apart from a favorable response rate
** Six of seven analysts rate CMPX stock "buy" or higher and one "hold"; their median PT is $7.50 - LSEG
** As of last close, CMPX stock has risen 1.9% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。